抗髓鞘相关糖蛋白神经病：最新进展
Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments.
作者信息
Morganroth Jennifer, Karam Chafic
机构信息
Department of Neurology, University of Pennsylvania.
出版信息
Neurol Clin Pract. 2025 Feb;15(1):e200368. doi: 10.1212/CPJ.0000000000200368. Epub 2024 Oct 8.
BACKGROUND
The purpose of this review is to give an update on myelin-associated glycoprotein (MAG) neuropathy.
RECENT FINDINGS
There are several recent developments in anti-MAG neuropathy, with the major one being the retrospective analysis of 50 clinical trials that showed that at least a 50% reduction in anti-MAG levels is associated with a therapeutic response. Other updates address antibody levels needed for a positive test, response, and exacerbations to therapy and the type of antibody more associated with malignancy.
IMPLICATIONS FOR PRACTICE
Anti-MAG neuropathy is heterogeneous, and the natural history of the disease continues to be refined. Treatment options are being explored for refractory disease.
背景
本综述的目的是更新关于髓鞘相关糖蛋白（MAG）神经病的信息。
最新发现
抗MAG神经病有几项最新进展，其中主要的一项是对50项临床试验的回顾性分析，该分析表明抗MAG水平至少降低50%与治疗反应相关。其他更新内容涉及阳性检测、反应和治疗加重所需的抗体水平，以及与恶性肿瘤更相关的抗体类型。
对实践的启示
抗MAG神经病具有异质性，该疾病的自然史仍在不断完善。正在探索针对难治性疾病的治疗选择。
Zotero 插件